University Hospitals Urology Institute | Strategic Alliance Partners

“These findings support the safety of vaginal estrogen for treatment of local menopause symptoms, even in high-risk women,” says Gabriella M. Rustia, MD.

"We think that radiation therapy is one of the best treatment options available for kidney cancer," says Nicholas Zaorsky, MD, MS.

"That's probably the biggest thing that I would say to somebody who's interested in urology is, do you think you can get on another patient's level?" says Emily Sopko, CNP.

"I like working alongside the residents, because they've taught me pretty much everything that I know about urology," says Emily Sopko, CNP.

"Often, we can do flexible cystoscopies for difficult Foley placements, or if we need to remove an indwelling stent at the bedside, I can assist with those things," says Emily Sopko, CNP.

"I'm able to really dedicate a lot of my time to patients and families for education," says Emily Sopko, CNP.

"When it came down to linking the clinical information with both biopsy reports as well as the prostatectomy pathology reports, we didn't have much of a challenge with that," says Randy A. Vince Jr, MD, MS.

"I'm very transparent with my patients by telling them these exist. I don't provide them because we don't have enough level of evidence or body of research supporting them," says Ramy Abou Ghayda, MD, MPH, MBA.

"What we found is that across the board, all 16 scores did relatively well with the association between an elevated polygenic risk score and prostate cancer incidence," says Randy A. Vince Jr, MD, MS.

“One thing is we’re trying to create an atmosphere in the center whereby men feel at ease, they're comfortable talking to their provider who is specialized in this field,” says Ramy Abou Ghayda, MD, MPH, MBA.

"I think digital therapeutics and virtual care are going to expand access," says David Sheyn, MD.

“I think ultimately, when we think about when do we deliver MDRT and to whom, it comes down to a goals of care discussion,” says Angela Jia, MD, PhD.

"We did discuss a couple of future research ideas, a number of which would have been controlling for those potential factors we thought could contribute to the increased UTI risk that we were not able to control for in the study like loss of commensal bacteria or anything of that nature," says David Gilbert.

"I think the main takeaway from this study is that prostate cancer is not as rare in trans women as we think it is, and that we really need to be giving this population the time that they deserve, and that they should be screened equally to their cis male counterparts," says Matthew Loria.

“The main takeaway is that we want to be working with [transgender and gender-diverse patients] the same way that we are working with cisgender folks,” says Matthew Loria.

"We ultimately found that trans women from between the ages of 50 and 65 who were on hormone therapy had a 2.5-fold decreased risk of prostate cancer compared with cis men," says Matthew Loria.

“What is becoming increasingly evident is that the traditional health care model is falling short for patients in rural regions,” says Ramy Abou Ghayda, MD, MPH, MBA candidate.

“Remarkably, relugolix demonstrated a faster return to baseline testosterone levels compared [with] traditional therapies, a crucial aspect for patients' quality of life post-treatment," says Daniel E. Spratt, MD.

"There are patients who are not able to be submitted to an MRI due to metallic artifacts or to some conditions that are not compatible with the performance of an MRI," says Leonardo Kayat Bittencourt, MD, PhD.

"There are situations where you can use a biparametric or noncontrast approach; most of them you will prefer still to use an approach with contrast," says Leonardo Kayat Bittencourt, MD, PhD.

"We have information today from a number of well-powered, well-designed prospective studies showing that performing an MRI before the decision to do the first biopsy adds value," says Leonardo Kayat Bittencourt, MD, PhD.

Daniel Spratt, MD, highlights the evolving paradigm of PET-based imaging agents in prostate cancer, with a focus on the impact of PSMA-PET imaging.

"What we found was that the obedience to the upgrading criteria of PI-RADS as they are today resulted in a better overall outcome for all the patients that were included in the study," says Leonardo Kayat Bittencourt, MD, PhD.

“I think that having the clinical context such as the PSA, the Gleason score, the other features that assess the aggressiveness of the disease can really help with some of these subtle findings that can be found on PET imaging,” says Daniel Spratt, MD.

"When we think about germline mutations, I think the number one thing that comes through for many urologists as well as oncologists is Lynch syndrome," says Laura Bukavina, MD, MPH, MSc.

"The main finding is that when you look at men with low testosterone, grouped 18 and above, we found that there is an association between low testosterone and kidney stone encounter diagnoses," says Austin Thompson.

From a show dog to a family of cats, let's see who some of the top medical professionals are spending their time with when they're not in the clinic.

Laura Bukavina, MD, MPH, offers a preview of noteworthy bladder and kidney cancer research to be presented at this year's Society of Urologic Oncology Annual Meeting.

"It's very important to build trust early on for a urologist and with a patient so that they're more likely to stay with a screening program," says Daniel E. Spratt, MD.